Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $107.25.

Several equities analysts recently commented on the company. Leerink Partners set a $100.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Evercore reaffirmed an “outperform” rating and set a $101.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Morgan Stanley upped their price objective on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th.

Insider Buying and Selling

In related news, Director Patrick J. Heron acquired 131,425 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were bought at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the purchase, the director owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the transaction, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. This represents a 5.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,136 shares of company stock valued at $4,352,029 in the last 90 days. Corporate insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIRM. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $32,000. MCF Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $33,000.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $102.01 on Friday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of -118.61 and a beta of 0.49. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $105.74. The firm’s 50-day simple moving average is $85.68 and its two-hundred day simple moving average is $75.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.